Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Oral bisphosphonate use and lung cancer incidence among postmenopausal women

Oral bisphosphonate use and lung cancer incidence among postmenopausal women ANNALS OF ONCOLOGY Tao, M. H., Chen, S., Freudenheim, J. L., Cauley, J. A., Johnson, K. C., Mai, X., Sarto, G. E., Wakelee, H., Boffetta, P., Wactawski-Wende, J. 2018; 29 (6): 1476–85

Abstract

Bisphosphonates are common medications for the treatment of osteoporosis in older populations. Several studies, including the Women's Health Initiative (WHI), have found inverse associations of bisphosphonate use with risk of breast and endometrial cancer, but little is known about its association with other common malignancies. The objective of this study was to evaluate the association of bisphosphonate use on the incidence of lung cancer in the WHI.The association between oral bisphosphonate use and lung cancer risk was examined in 151?432 postmenopausal women enrolled into the WHI in 1993-1998. At baseline and during follow-up, participants completed an inventory of regularly used medications including bisphosphonates.After a mean follow-up of 13.3?years, 2511 women were diagnosed with incident lung cancer. There was no evidence of a difference in lung cancer incidence between oral bisphosphonate users and never users (adjusted hazard ratio?=?0.91; 95% confidence intervals, 0.80-1.04; P?=?0.16). However, an inverse association was observed among those who were never smokers (hazard ratio?=?0.57, 95% confidence interval, 0.39-0.84; P?

View details for PubMedID 29617712

View details for PubMedCentralID PMC6005043